Key facts
- It has raised $10.6M; the latest was Early Stage VC in Jul 2025.
- Notable investors include Creative Destruction Lab, University of Toronto, Matter (Consulting Services (B2B)), CELS Valley Ready, National Research Council of Canada Industrial Research Assistance Program — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Canurta Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Canurta Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Canurta Therapeutics
Operator of a biotechnology company intended to reverse chronic disease progression through multi-target botanical therapeutics. The company offers AI-enhanced discovery tools, proprietary bioprocessing of rare polyphenols, and precision formulation strategies, enabling patients with neurodegenerative and inflammatory conditions, improved treatment options that address complex disease mechanisms with efficacy.
- Sector
- Healthcare
- HQ
- Mississauga, Canada
- Founded
- 2021
- Employees
- 16
- Website
- canurta.com/
- Ownership
- Privately Held (backing)
Canurta Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Canurta Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Canurta Therapeutics in its N-PORT filings yet. We sweep new filings monthly.